In ₹ Crore except Per Share Latest Annual	CONCORDBIO FY26	BIOCON FY26	DIVISLAB FY26	CAPLIPOINT FY26	Peer Average
Valuation — at last close
P/E	49.66×	124.79×	99.89×	◆ 28.17×	84.28× -41%
P/B	6.38×	◆ 1.68×	15.28×	5.04×	7.33× -13%
EV/EBITDA	33.90×	◆ 20.42×	73.43×	22.47×	38.78× -13%
Market Cap	₹12,874 Cr	₹57,043 Cr	₹2.56L Cr	₹18,058 Cr	₹1.10L Cr -88%
Growth
Revenue CAGR 3Y	—	◆ 14.85%	10.78%	14.25%	13.29%
Revenue CAGR 5Y	—	◆ 18.96%	8.67%	15.56%	14.40%
Net Income CAGR 3Y	—	-16.91%	12.09%	◆ 19.89%	5.02%
Revenue YoY (latest Q)	25.10%	10.00%	◆ 27.80%	19.63%	19.14% +31%
Net Income YoY (latest Q)	10.32%	53.36%	◆ 65.50%	18.79%	45.88% -78%
Profitability
EBITDA Margin	◆ 34.83%	20.41%	32.59%	34.79%	29.26% +19%
Net Income Margin	24.57%	2.18%	24.32%	◆ 29.71%	18.74% +31%
Return on Common Equity	13.63%	1.39%	16.19%	◆ 19.92%	12.50% +9%
Return on Capital Employed	14.96%	3.19%	17.80%	◆ 20.97%	13.99% +7%
Return on Assets	12.14%	0.60%	13.89%	◆ 17.91%	10.80% +12%
Credit & Quality
Total Debt/Equity	◆ 0.00×	0.40×	0.00×	0.00×	0.13× -100%
Interest Coverage	◆ 1034.40×	1.51×	129.48×	790.90×	307.30× +237%
Scale — latest FY
Revenue / Total Income	₹1,055 Cr	₹16,927 Cr	₹10,560 Cr	₹2,187 Cr	₹9,891 Cr -89%
Net Income	₹259 Cr	₹369 Cr	₹2,568 Cr	₹650 Cr	₹1,196 Cr -78%
Total Assets	₹2,235 Cr	₹63,651 Cr	₹20,033 Cr	₹4,045 Cr	₹29,243 Cr -92%
EPS	₹24.78	₹2.82	₹96.75	₹84.36	₹61.31 -60%
Book Value per Share	₹192.81	₹209.94	₹632.49	₹471.9	₹438.11 -56%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.